<DOC>
	<DOCNO>NCT02398461</DOCNO>
	<brief_summary>This Phase 1 , multi-center , double-blind , randomize , placebo-controlled , dose-escalation study subject relapse Multiple Sclerosis ( MS ) . The primary outcome safety tolerability single dose rHIgM22 relapse MS subject .</brief_summary>
	<brief_title>An Intravenous Infusion Study rHIgM22 Patients With Multiple Sclerosis Immediately Following Relapse</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Males female ( 1870 year age ; &lt; 104 kg ) Capable give informed consent Meet diagnostic criterion MS , define revise ( 2010 ) McDonald criterion Present clinical acute relapse define new worsen neurological symptom attributable MS precede stable improve neurological state least 30 day , associate fever infection , last least 24 hour accompany objective physical ( neurological ) exam find confirm Investigator Has least one new , identifiable , measurable active lesion MRI ( Gd+ ) meeting criterion image charter . Certain specified comorbidities ( include pregnancy ) Taking certain proscribed medication A medical regimen change month prior screen Inability undergo requisite MRI evaluation Drug alcohol abuse Any reason , opinion Investigator , subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>